In our efforts to produce monoclonal antibodies that recognize cell-surface antigens expressed by hematopoietic precursor and stromal cells, we generated a monoclonal antibody, 7.1, which recognizes a 220-to 240-kD cell-surface protein whose N-terminal amino acid sequence is identical to the rat NG2 chondroitin sulfate proteoglycan molecule. This chondroitin sulfate proteoglycan, previously reported to be expressed by human melanoma cells, was not found to be expressed by normal hematopoietic cells, nor was it expressed on the cell surface of cell lines of hematopoietic origin including cell lines with 11q23 abnormalities. It was found on the cell surface of acute myeloid leukemia (AML) blasts and cell lines derived from nonhematopoietic tissues. Samples of leukemic marrow from 166 children with AML enrolled on Childrens Cancer Group protocol 213 were evalu-HE ACUTE myeloid leukemias (AML) are a heterogeneous group of diseases with diverse patterns of cellsurface antigen expression. Numerous studies have extensively described the maturation-linked expression of cell-surface antigens including those antigens associated with normal myeloid and lymphoid differentiation as well as the CD34 antigen, the c-kit receptor, and P-glycoprotein, the protein encoded by the multiple drug resistance gene."' Recent studies using multidimensional flow cytometric analysis have clearly shown that during normal myeloid lineage differentiation, cells exhibit a highly reproducible and orderly pattern of cell-surface antigen expression.' Although the cell-surface antigens expressed by AML blasts are the same antigens expressed on normal hematopoietic cells, the patterns of cell-surface antigen expression are aberrant in malignant myeloid cells.'"' To date, investigators have not identified novel cell-surface molecules on AML blasts that are not expressed during normal hematopoietic development.
Although the identification of the cell-surface antigens expressed by leukemic blasts may aid in distinguishing leukemias of myeloid lineage from those with lymphoid lineage differentiation, the use of leukemic blast cell surface antigen expression has been of little prognostic value in childhood AML.' Similarly, cell-surface antigen expression by AML blasts has been of little value in monitoring for residual disease, although recent multidimensional flow cytometric studies in adult patients with AML have demonstrated that the identification of aberrant immunophenotypic patterns may detect residual leukemia with greater sensitivity and may be capable of predicting relapse of disease."
In this report, we describe the expression of a 220-to 240-kD cell-surface chondroitin sulfate proteoglycan molecule, previously described on human melanoma and identified by amino acid sequencing as the human homologue of the rat NG2 (hereafter referred to as NG2), that is not expressed by normal hematopoietic cells but is selectively Hammond, and Irwin D. Bernstein ated for cell-surface expression of this proteoglycan molecule. In 18 of 166 (11%) patient samples, greater than 25% of leukemic blasts expressed the NG2 molecule. These 18 patients had a poorer outcome with respect to survival (P = .002) and event-free survival (P = .035) with an actuarial survival at 4 years of 16.7%. Blast cell expression of the NG2 molecule was strongly associated with French-AmericanBritish M5 morphology ( P < .0001) and abnormalities in chromosome band llq23, site of the MLL gene. These results show that the NG2 molecule is expressed by malignant hematopoietic cells that have abnormalities in chromosome band 11q23, suggesting that antibody 7.1 may be useful in the rapid identification of this group of poor-prognosis patients. 0 1996 by The American Society of Hematology.
expressed by leukemic blast cells from a subpopulation of children with AML who have a poor prognosis. These AML blasts show predominately French-American-British (FAB) M5 morphology and have abnormalities in chromosome band 1 lq23, the site of the MLL gene, the function of which is currently ~n k n o w n . '~-'~ 62 . On day 6.5 spleen cells were fused with SP2/0 myeloma cells using previously described techniques.21 Ig-producing hybrids were selected on the basis of reactivity with another SV-40 transformed human marrow stromal cell line, Bhasin, which were grown on glass slides and fixed with 2% paraformaldehyde and 0.1 % glutaraldehyde. Ig-producing hybridomas were also selected based on nonreactivity with human PB monocytes and granulocytes as determined by flow microfluorimetry. Selected clones were expanded and used for ascites production in Balb/c mice as previously described." Antibody 7. I ascites was purified by high-pressure liquid chromatography (HPLC) and determined to be an IgG I molecule using described immunodiffusion techniques.22
Radiolabeling, immunoprecipitation, and gel analysis. Cells were surface labeled by lactoperoxidase iodination and radioimmunoprecipitation studies were performed as previously de~cribed.",'~ Briefly, cells were washed three times with phosphate-buffered saline (PBS) pH 7.0 and suspended to S X IO7 cells/mL in PBS pH 7.0 containing 10 mmol/L glucose (J.T. Baxter, Phillipsburg, NJ) (90 mg/lO mL PBS). ' ' ' 1 (mCi), glucose oxidase 20 pL (S mg/mL) (Calbiochem, San Diego, CA), and lactoperoxidase 20 pL (70 1U/ mL) (Calbiochem) were added, in order, to I mL of cells at room temperature. The cells were incubated for 20 to 25 minutes at room temperature and then washed three times with PBS. The radiolabeled cells were lysed on ice for 30 minutes by resuspension in S0 mmol/ L Tris-HCI pH 7.6 (Sigma, St Louis, MO) containing 150 mmollL NaCI, 2% Triton X-100 (Sigma), 2 mmol/L phenylmethylsulfonylfluoride (Boehringer Mannheim, Indianapolis, IN), and l % (wthol) aprotinin. The lysate was centrifuged and the supernatant was precleared with an isotype matched control antibody of irrelevant specificity (3 I .A) conjugated with sepharose conjugate (100 pL of a 1: 1 suspension containing SO pg antibody) for 20 minutes at 4°C." The radiolabeled, precleared lysate (200 pL) was then incubated with MoAb 7.1-sepharose conjugate for 2 hours at 4°C. The beads were washed twice with lysis buffer (SO mmollL Tris pH 8.0, 0.15 mol/ L NaCI, 20 mmol/L EDTA, 2 mmol/L phenylmethylsulfonylfluoride, 2% Triton X-100) and twice with S0 mmol/L Tris-HCI wash containing O S % NP-40 (Sigma) and 450 mmollL NaCI.
The radiolabeled protein was released by addition of 60 pL sample electrophoresis buffer (0.125 mol/L Tris-HCI, 2.5% sodium dodecyl sulfate [SDS] . 2S% glycerol, 0.002% bromophenol blue with or without 2.S% 2-mercaptoethanol) and was heated at I00"C for S minutes. Immunoprecipitated proteins were separated by electrophoresis in 8% polyacrylamide gels in the presence of SDS under reducing and nonreducing conditions." The gels were dried and radiolabeled bands identified by radioautography.
Protein microsequencing. Due to the high level of expression of the NG2 molecule by the human cervical carcinoma cell line HeLa, this cell line was used for microsequencing studies. HeLa cells were grown in a bioreactor system (Applikon, Sciedam, Holland) with the preparation of 10, 35-mL cell pellets. Cell pellets were frozen at -80°C until use, then thawed at room temperature. Cell pellets were maintained at 4°C after thawing and washed with PBS without calcium or magnesium. After a 10-minute, I ,500-rpm spin, the cells were resuspended in 1 % Triton XlPBS (Pierce, Rockford, IL) plus protease inhibitors I mmol/L phenylmethylsulfonyl fluoride (PMSF) and S mmol/L EGTA. The cells were vortexed at 4°C and spun at 30 kg for 30 minutes at 4°C. The supernatant was removed and placed over an affinity column of 5.0 mg/mL 7. I MoAb per mL Affi-IS (Bio Rad, Hercules, CA). The column was washed with PBS/l% Triton, then 2 mol/L NaCUPBS followed by washes of PBS, 2 mol/L urea/PBS, then PBS. Protein was eluted from the column in 0.3-mL fractions with 100 mmol/L glycine, pH 2.0. Fractions with protein were determined by gel with fractions containing protein concentrated by a l00 mwco Centricon (Amicon, Beverly, MA). The protein was boiled with reducing SDS sample buffer. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was prepared according to the method of Lammeli with samples run on a 7 4 , 0.5-cm thick gel. After electrophoresis the gel was stained with amido black in H 2 0 . Stained gel was analyzed by eye and the 220-to 240-kD band and blank bands were excised with a scape1 and digested according to the method of Rosenfeld et al. '7 Briefly, the excised bands were washed twice with IS0 p L 50% acetonitrile in 200 mmol/L ammonium carbonate. pH 8.9, for 20 minutes at 30°C and semidried at room temperature. The gel slices were partially rehydrated with IS0 p L of 200 mmoVL ammonium carbonate, pH 8.9, containing 0.02% Tween 20. Then, 2 pL trypsin in 200 mmol/ L ammonium carbonate, pH 8.9, was added (approximately 1:2S). The gel slices were placed in an Eppendorf tube and digested for 24 hours at 37°C. The digestions were stopped by adding I .S p,L of trifluoroacetic acid. Peptides were recovered by two 20-minute 37°C extractions using 60% acetonitrile and 0.1% trifluoroacetic acid. Before loading onto reverse phase, the extracts were combined and concentrated to a volume of approximately 20 pL in a SpeedVac (Savant, Farmingdale, NY). The eluted peptides were separated by reverse phase on a S00 pmollL I.D. X 25 cm packed with Vydac C-18 material capillary column (Vydac, Hesperia, CA) and compared to the blank digest. Elution was monitored by MALDI-TOF/ MS N-terminal sequence analysis performed on a 473 AB1 sequencer (ABI, Foster City, CA) according to manufacturer's instructions.
MoAbs. MoAbs to cell-surface antigens associated with lymphoid and/or myeloid lineage differentiation (CD2, 3, 4. S, 7, 8, 9, 10. IS, 19, 20, 33, 34, 36, glycoprotein Ib) were used in the form of ascites fluid at dilutions of 1 :2S0 to 1 : 1,000 or as HPLC purified antibody. The specificity of the antibodies used was previously described.' MoAb 7.1 was used in the form of HPLC purified antibody at a concentration of I O pg/mL. Indirect immunofluorescence studies. Diagnostic leukemia marrow cells, normal PB and BM, and cells lines were stained using previously described indirect immunofluorescent antibody staining & techniques.' Briefly, after frozen marrow samples were thawed in RPM1 with 10% calf serum (Hyclone. Logan UT) and I O 0 U/mL deoxyribonuclease I type I1 (Sigma), the cells were incubated for 30 minutes at 4°C with MoAb diluted in PBS plus 2% human AB serum (GIBCO Laboratories, Grand Island, NY). washed with cold PBS plus 2% human AB serum, then incubated with a 1:40 dilution of affinity-purified fluorescein isothiocyanate-conjugated goat-antimouse IgM plus IgG antibody (Tago Inc. Burlingame, CA) for 30 minutes at 4°C. As negative controls. cells were stained with isotype identical antibodies of irrelevant specificity: TI ID7 or H12C12 (IgM, antimouse Thy 1.1 and Thy 1.2, respectively), IA14 (IgGZa, antimouse Thyl.1). or 31.A (IgGI, antimouse Thyl.2). Cells were washed twice with PBS plus 2% human AB serum. stained with 8 pg/mL propidium iodide (Sigma), washed twice, and kept at 4°C until flow cytometric analysis. Cells were analyzed on a modified Becton Dickinson FACS II flow cytometer (Becton Dickinson, Oxnard, CA). A total of 5 , o O propidium iodide-negative events with forward and 90" light scatter properties consistent with blast-sized cells were analyzed for each antibody. A leukemic sample was considered positive for antigen expression if z2S% of cells expressed a fluorescence intensity greater than 95% of the fluorescence intensity of cells stained with the isotype matched control antibody.
Pmients. CCG protocol 213 for children more than I month and less than 21 years of age at diagnosis with previously untreated AML was conducted from January 1986 until February 1989." Five hundred ninety-one patients were enrolled in the study. Immunophenotyping studies for myeloid and lymphoid lineage associated antigens and for the presence of the 7. I antigen were performed on all CCG 213 patients for whom a sample was available in the CCG Reference Laboratory (N = 166, 28.1% of study patients). Patient follow-up is ongoing with a median time of 1.046 days.
Diccgnosi.r. A diagnosis of AML was made at the institution of origin based on standard morphologic and cytochemical criteria including Wright-Giemsa, a-naphthol butyrate esterase. chloracetate esterase, periodic acid Schiff, peroxidase, and Sudan Black stains. The morphologic and histochemical diagnosis of AML was confirmed by a single review pathologist in a central CCG reference laboratory.
Detection of MLL gene recrrrctngement l>y Snccthern nrtrdysis. Genomic DNA was extracted. digested with restriction endonucleases, and analyzed by Southern blotting as described."' Digestions were performed with EcoRI, Hindlll, and BnmHI. The probes used to detect rearrangement of the MLL gene at chromosome band I Iq23 have been previously described."' Briefly. P/S4 and 98.40 are singlecopy genomic probes located telomeric and centromeric. respectively, to the der I 1 breakpoint of the RS4: 1 I cell line. and 4.1E is a subclone of the EcoRl fragment of MLL located just telomeric to the region recognized by P/S4. To pre-anneal repetitive sequences recognized by the 4.2E probe. 400 pg/mL of total human DNA (Sigma) was included in the hybridization solution. DNA isolated from RS4; 1 I or B I cells was used as a positive control. and DNA from normal individuals PB leukocytes was used as a germline control.
Statisticcd nnulysis. Outcome was assessed by induction rate. death during induction, survival, disease-free survival (DFS). and survivallDFS after remission induction. Potential differences in the clinical features (age at diagnosis, white blood cell count at diagnosis [WBC] , and FAB classification) and outcome parameters between the groups of patients whose blasts were immunophenotyped and those whose cells were not evaluated were assessed using Chi-square tests. Fisher's exact tests were used to assess the significance of difference in induction rate and death during induction. A Chi-square test for trend in proportions was used to analyze survival. DFS. as well as survival/DFS after remission induction. Actuarial survival estimates were calculated with the Kaplan-Meier product limit with the result expressed as the probability of survival at 4 years 2 2 SD (Greenwood method) which encompasses the 9 5 9 confidence interval.
RESULTS
Amino acid sequence of the 220-to 240-kD protein itntmcnoprecipitated by antihody 7. l . Internal sequence analysis of the peptides generated from the protein precipitated by MoAb 7.1 (Fig 1) showed: AQLSVVDPDSAPGEIEY-EVQR. Comparison of this sequence with that of rat NG2'" shows 100% sequence homology over the 21 amino acids sequenced.
Cell-surface expression of the NG2 tnolecltle 17y normal hematopoietic cells. Antibody 7.1 did not react with PB lymphocytes, monocytes, granulocytes, platelets. or red blood cells. Likewise. multicolor flow cytometric analysis found no reactivity of this antibody with any population of cells within normal adult marrow (Fig 2) , including the CD34 subpopulation of precursor cells (data not shown). T (-4. cells that were activated by exposure to phytohemagglutinin (PHA, 2 &mL; GIBCO) and 20% human interleukin-2 (IL-2) (Lymphocult-T; Biotest Diagnostics, Frankfurt, Germany) were also found to be nonreactive with the antibody.
Cell-surface expression of NG2 by cell lines. All cell lines of hematopoietic origin that were tested (KG1, KGla, HEL, Jurkat, HSB2, K562, Raji, U937, HL-60, Daudi, Nalm6, and CEM) did not react with the 7.1 antibody (Table   1 ). In addition, the RS4; 11 cell line, which has an abnormality in chromosome band llq23, did not react with antibody 7.1. However, the NG2 molecule was detected on the cell surface of a variety of transformed and untransformed cell lines of nonhematopoietic origin. These cell lines were derived from smooth muscle (MYO-13, ULTR-16, AA LTR 16-2, AVSMC), marrow stroma (Bhasin, Pinkney, Readus, Stenburg), cervical carcinoma (HeLa), and epithelial cells (Caski) ( Table 1, Fig 2) . Although the NG2 molecule was not expressed by the murine fibroblast cell line NIH 3T3, it was expressed by CV-l and COS cell lines derived from nonhuman primate kidney cells.
Cell-surface expression of NG2 by AML blast cells. Samples of leukemic marrow from 166 children with AML were evaluated by flow microfluorimetry for cell-surface expression of the NG2 chondroitin sulfate proteoglycan. In 18 patient samples (1 l%), greater than 25% of leukemic blasts expressed the NG2 molecule (Fig 2) .
Study population. To exclude a selection bias among patients who had marrow samples available for analysis, we compared the clinical characteristics and outcome in patients whose leukemia cells were immunophenotyped and all evaluable study patients. There was no statistical difference between the 166 patients tested and the full cohort of 591 eligible patients enrolled on study with respect to induction rate (P = .21), death during induction (P = S l ) , survival (P = .22), disease-free survival (DFS) (P = .31), age at diagnosis (P = .77), WBC at diagnosis (P = .43), FAB classification (P = .95), and percentage of blasts in marrow (P = .087).
Clinical and laboratory characteristics qf patients with NG2 molecule positive blast cells. When we analyzed the clinical characteristics of the 18 patients whose marrow contained greater than 25% 7.1 positive blasts cells (Table 2) , we found that blast cell surface expression of the NG2 molecule was associated with a younger age at diagnosis ( P = .048) but was not associated with the WBC at diagnosis. Expression of NG2 was strongly associated with FAB M5 morphology (P < .001) with 12 of 18 samples being classified as FAB MS. In 4 patients, an FAB class could not be assigned by the central CCG pathologist who reviewed all marrows for enrolled study patients. The remaining two patient samples had FAB M4 morphology. We found no association between NG2 expression and the cell-surface expression of antigens associated with myeloid or lymphoid lineage differentiation (CD2, 3, 4, S, 7. 8, 9, 10, 15, 19, 20, 33, 34, 36, or glycoprotein Ib) .
There was a strong association between blast cell expression of the NG2 molecule and abnormalities involving chromosome band 1 lq23. Review of the cytogenetic results by a central reviewer (D.A.) demonstrated that of the 166 patients in this study, 105 (63%) patients had cytogenetics available for central review. Cytogenetic abnormalities in chromosome band 1 lq23 were present in 13 patients, 27 patients had a normal karyotype, 65 patients had abnormalities other than band 1 lq23, and 61 patients did not have cytogenetic results available for review or the cytogenetic preparation was deemed unacceptable by the central review cytogeneticist. Nine of the 13 patients whose blasts had an abnormality in chromosome band 1 lq23 were NG2 molecule positive (patients 7 , 8, 9, 10, l 1, 12, 16, 18) (Table 3 ) with 4 patients having blasts that were NG2 molecule negative but demonstrated 1 lq23 abnormalities (patients 19 through 22) (Table 4 ). In 5 patients (patients 1, 2, 4, 5 , 14) whose blasts were 7.1 antigen positive but did not have cytogenetic evidence of 1 lq23 abnormalities, additional diagnostic leukemia samples were available in the AML Reference Laboratory. Southern blot analysis of these 5 patients' leukemic blasts showed that the MLL gene at llq23 was rearranged in all 5 samples (Fig 3) . abnormalities but whose blasts did not express the NG2 molecule were not significantly different from the group of patients with NG2 positive blasts ( Table 6 ). The age and WBC at diagnosis was similar in the two populations of patients. Two patients' blasts had FAB M5 morphology, 1 patient had FAB M4 morphology, and 1 patient's leukemia could not be assigned to an FAB subclass by the central review pathologist.
Outcome of patients with NG2 molecule positive blast cells. The outcome of the 18 patients with 7.1 positive blasts cells was significantly worse than the 148 patients whose blasts cells did not express the NG2 chondroitin sulfate proteoglycan (Fig 4) . Patients with blasts that expressed this chondroitin sulfate proteoglycan molecule had a greater rate of death during induction (P = .037), poorer survival (P = .002), DFS ( P = .035), and an actuarial survival rate at 4 years of 16.7% compared with an actuarial survival of 44.5% for patients whose blasts did not express this molecule.
The cause of death in the 15 patients whose blasts expressed the NG2 molecule was variable (Table 2) . Nine patients died of progressive leukemia, 3 died of infection, 2 died of hemorrhage, and 1 patient died of renal failure. Although the number of patients is small, the causes of death are not different than those expected for children with AML.
DISCUSSION
In our efforts to identify antigens that may be shared by immature hematopoietic precursor and stroma cells, we generated an MoAb, 7.1, which recognizes a 220-to 240-kD cell-surface protein whose N-terminal amino acid sequence is identical to the rat NG2 chondroitin sulfate proteoglycan molecule. This chondrotin sulfate proteoglycan molecule was found to be expressed by childhood AML blasts and cell lines of nonhematopoietic origin, but was not demonstrated on the cell surface of normal hematopoietic cells or cell lines of hematopoietic origin, including the cell line RS4; 11 which has abnormalities in chromosome band 1 lq23.
Proteoglycans are a large class of molecules that are found on the cell surface or the extracellular matrix and are thought to have important functions in promoting and inhibiting cell adhesion, transmembrane signaling, cellular migration, and cellular proliferation. The chondroitin sulfate proteoglycans class of molecules have been shown to be inhibitors of cell adhesion and migrati~n~"~' and are thought to serve as barriers to cell migration in neural crest pathway^.^^.'^"^ The rat NG2 molecule is a large 400-to 800-kD (core protein of 300 membrane spanning proteoglycan whose primary structure shows a large extracellular domain, a single transmembrane domain, and a short cytoplasmic tal3' The sequence of NG2 is unique and bears few similarities to other known proteins. Comparison of the amino-terminal sequences of the human melanoma proteoglycan, recognized by MoAb 9.2.27,""' with that of rat NG2 confirm that the melanoma-associated proteoglycan molecule is the human homologue." Additionally, preliminary experiments have shown that antibodies 9.2.27 and 7.1 are cross-reactive on cell lines that express the NG2 molecule (data not shown).
Unlike other cell-surface antigens expressed by childhood AML blasts,3 expression of this molecule was of strong prognostic significance. Unlike childhood acute lymphoblastic leukemia (ALL) where many clinical and laboratory parameters have been identified that predict for relapse of disease, few clinical or laboratory parameters have been identified in children with AML that are predictive of outcome. However, like childhood ALL, a high WBC at diagnosis is the strongest predictor of a poor response to therapy!'
Other previously described factors that have limited prognostic value in children with AML include extramedullary disease at diagnosis, age greater than 15 years at diagnosis, central nervous system disease at diagnosis, early response to therapy with less than 5% blasts on day 14 of treatment, Down syndrome, splenomegaly, coagulation abnormalities, and karyotypic abnormalities including -7, 7q-, and t(8;21) .40-47 A univariate analysis of the sub-group of children with AML whose blasts expressed the chondroitin sulfate proteoglycan NG2 molecule clearly demonstrated that they have a worse outcome and respond poorly to the therapy that was more effective for children whose blasts did not express this molecule. The identification of this poor-prognosis group of patients suggests that therapeutic protocols may in the future be stratified for this group of patients as they may benefit from alternative types of therapy.
Although characteristic patterns of antigen expression have been identified for several FAB subclasses,4*-" overall, a clear correlation between immunophenotype and FAB classification has not been documented. Similarly, with rare ex- ceptions such as an association between the co-expression of the natural killer (NK) cell antigen, CD56, and the Blineage antigen, CD19, by FAB M2 leukemias with the t(8;21)(q22;q22),55 there are no clear correlations between cell surface antigen expression and specific cytogenetic abnormalities. Therefore, the strong association between cellsurface expression of the NG2 molecule and FAB M5 differentiation (P < .001) was striking.
However, the most striking finding in this study was the demonstration that cell-surface expression of the NG2 molecule was associated with abnormalities in the MLL gene located at chromosome band l lq23. Interestingly, our findings that the expression of the NG2 molecule is associated with a younger age at diagnosis, FAB M4M5 morphology, and alterations in chromosome band llq23 are consistent with those of Sorensen et al,s6 who were able to show that infants with AML who had rearrangements in the MLL gene were very likely to have monocytic and myelomonocytic (FAB M5, M4 respectively) differentiation.
The absence of NG2 expression on the RS4; 1 I cell line (and MV4; 11 cell line; unpublished data, June 1992) is not unexpected given the finding that the blast cells from four AML patients contained llq23 abnormalities but did not have detectable cell surface expression of NG2. Cell lines derived from AML blasts that contain abnormalities in chromosome band 1 lq23 were not studied. The results from the AML patient samples and the ALL-derived RS4; 11 cell line suggest that NG2 expression is associated with some abnormalities involving chromosome band llq23, but not all 1 lq23 abnormalities. The further identification and characterization of these subgroups is currently unknown. Further- more, the exact relationship between NG2 expression and the presence of MLL gene rearrangements will require the study of a large cohort of patients in whom cytogenetic, molecular genetic, and flow cytometric data are all available. Our findings suggest that the NG2 molecule detected by antibody 7.1 is aberrantly expressed within malignant hematopoietic cells, possibly related to expression of an important gene at, or regulated by, the llq23 locus. Recent data indicate that the gene at chromosome band 1 1q23 (MLL, HTRX-I , ALL-l, HRX) is an evolutionarily, highly conserved gene homologous to the Drosophila trithorax gene, that is frequently involved in acute l e~k e m i a , '~"~~~~.~"~~ particularly in those leukemias that arise during infancy.
In Drosophila, the zinc finger-like domains of the predicted amino acid sequence suggests that the trithorax protein binds to This transcription factor is thought to control homeotic genes and it has been suggested that the human homologue of the trithorax gene is involved in the control of genes which effect cellular differentiation, potentially suggesting that alterations in this gene may play a role in malignant transformation. Nakamura et al6I have examined the reciprocal chromosome translocations involving the ALL-l (MLL) gene at 1 lq23 and genes from chromosome 4 (AF-4), chromosome 9 (AF-9), and chromosome 19 (ENL), the commonly associated partner chromosome in translocations involving 1 lq23. Sequence analysis of the AF-4, AF-9, and ENL proteins demonstrated nuclear targeting sequences, serine-and proline rich regions, and stretches abundant in basic amino acids, suggesting that the different proteins fused to ALL-l may provide similar functional domains. In a study of childhood ALL that accompanies this manuscript, Behm et a1 have clearly shown that the NG2 molecule is expressed only in ALL leukemic blasts that have reciprocal translocations involving the MLL gene [t(4; ll)(q21;q23) and t(l I ; 19)(q23;p13)]. Our results for childhood AML are less clear. Although the NG2 molecule was expressed on blasts with the reciprocal translocations t( I 1 ; 19)(q23; p1 3) and t(9; ll)(p22;q23), it was also expressed in blasts with the translocation t( 1 1 ; 17)(q23; q11.2) (patient 18) and t(l0; l l)(p?;q?) (patient 4). Although translocations involving chromosome band 1 lq23 and chromosome 19 occur in both ALL and AML, the t( 11 ; 19)(q23;p13.3) occurs primarily in ALL whereas t(l1; 19)(q23;p13.1) occurs only in AML.'j2 It is not known if the proteins encoded by the genes at chromosome 17q11.2 and the site on chromosome lop? contain functional domains such as those encoded on chroFor personal use only. on November 11, 2017. by guest www.bloodjournal.org From mosomes 4, 9, and 19. Interestingly, in the 4 patients whose leukemic blasts had alterations in chromosome band 1 lq23 but were NG2 cell surface negative, only l patient had a reciprocal translocation involving chromosome 9 (patient 19). One patient had a translocation of chromosome 17, but in band q25 rather than qll.2 as seen in NG2 molecule positive patient 18. One patient had a reciprocal translocation involving chromosomes llq23 and lp32 (patient 22), and one had a deletion in chromosome band llq23. Therefore, significant heterogeneity exist in the partner chromosome involved in translocations of chromosome band l lq23, making an association between a specific translocation and expression of NG2 difficult to discern. Therefore, we hypothesize that the gene which encodes the NG2 molecule is controlled by a transcription factor that is encoded by the trithorm-like MU, gene located on chromosome band 1 lq23
and that certain types of alterations in this gene result in the aberrant expression of the NG2 molecule.
It is also possible that the NG2 molecule is normally expressed at some stage of normal human embryonic hematopoietic development. If this is the case, cellular transformation that disrupts the 1 lq23 locus may result in the aberrant, continued expression of the NG2 molecule. This hypothesis is supported by data in the rat embryo which suggests that the expression of NG2 is developmentally regulated with its highest expression in neural and extraneural tissues on primative, proliferating cells with decreased expression on more differentiated cells.63
Because the NG2 molecule has not been detected on any normal hematopoietic tissue, the NG2 molecule may prove to be useful in the diagnosis of the subpopulation of childhood AML patients whose blasts have abnormalities in chromosome band 1 lq23, the detection of minimal disease, and could potentially serve as a target for novel leukemia-specific therapeutic modalities.
